Medications that meet spec. manual requirments for VTE-1

XMLWordPrintable

    • Type: Hosp Inpt eCQMs - Hospital Inpatient eCQMs
    • Resolution: Answered
    • Priority: Moderate
    • Component/s: None
    • None
    • Mara McCarville
    • 9096515715
    • Loma Linda University Medical Center
    • Hide
      Thank you for your inquiry regarding CMS108: Venous Thromboembolism Prophylaxis (VTE-1). You can review all the value sets within the terminology section of the measure’s specifications, and plug the indicated OIDs to the VSAC (https://vsac.nlm.nih.gov/) to review the qualifying terminology and medications for the measure.

      At this time, there is no approved indication to use Oral Factor Xa (Apixaban or Xarelto) for venous thromboembolism (VTE) prophylaxis with the exception of patients with history of either atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), or hip/knee replacement surgery. The measure specifications are consistent with the approved indications for Oral Factor Xa . If the FDA-approved indications should change in the future to include all hospitalized medical and surgical patients, then the measure specifications will be updated.

      Pradaxa (Dabigatran) is found in the value set "Direct Thrombin Inhibitor” RXNORM Value Set (2.16.840.1.113883.3.117.1.7.1.205) and is indicated in the logic under the low-risk indicator for VTE.
      Show
      Thank you for your inquiry regarding CMS108: Venous Thromboembolism Prophylaxis (VTE-1). You can review all the value sets within the terminology section of the measure’s specifications, and plug the indicated OIDs to the VSAC ( https://vsac.nlm.nih.gov/ ) to review the qualifying terminology and medications for the measure. At this time, there is no approved indication to use Oral Factor Xa (Apixaban or Xarelto) for venous thromboembolism (VTE) prophylaxis with the exception of patients with history of either atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), or hip/knee replacement surgery. The measure specifications are consistent with the approved indications for Oral Factor Xa . If the FDA-approved indications should change in the future to include all hospitalized medical and surgical patients, then the measure specifications will be updated. Pradaxa (Dabigatran) is found in the value set "Direct Thrombin Inhibitor” RXNORM Value Set (2.16.840.1.113883.3.117.1.7.1.205) and is indicated in the logic under the low-risk indicator for VTE.
    • CMS0108v13
    • CMS0108v12

      We are interested to know if the following medications will meet the measure specifications for VTE prophylaxis as it relates to VTE-1 eCQM.
      • Apixaban
      • Pradaxa
      • Xarelto
      Please advise

            Assignee:
            Augustine Weber
            Reporter:
            Mara McCarville (Inactive)
            Votes:
            0 Vote for this issue
            Watchers:
            3 Start watching this issue

              Created:
              Updated:
              Resolved:
              Solution Posted On: